» Articles » PMID: 18923523

Somatic and Germline Activating Mutations of the ALK Kinase Receptor in Neuroblastoma

Abstract

Neuroblastoma, a tumour derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumours in childhood. It usually occurs sporadically but familial cases are observed, with a subset of cases occurring in association with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene. Here we conducted genome-wide comparative genomic hybridization analysis on a large series of neuroblastomas. Copy number increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was observed recurrently. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Through subsequent direct sequencing of cell lines and primary tumour DNAs we identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots. Germline mutations were observed in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene. Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation. Altogether, these data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.

Citing Articles

Systematic Comparison of FBS and Medium Variation Effect on Key Cellular Processes Using Morphological Profiling.

Lebedev T, Mikheeva A, Gasca V, Spirin P, Prassolov V Cells. 2025; 14(5).

PMID: 40072065 PMC: 11898771. DOI: 10.3390/cells14050336.


15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.

Elmenawi S, Fawzy M Curr Oncol Rep. 2025; .

PMID: 40064818 DOI: 10.1007/s11912-025-01650-w.


ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.


Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma.

Chugh S, Tien J, Hon J, Kenum C, Mannan R, Cheng Y Neoplasia. 2025; 60:100964.

PMID: 39900433 PMC: 11846495. DOI: 10.1016/j.neo.2024.100964.


Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis.

Han M, Niu H, Duan F, Wang Z, Zhang Z, Ren H Front Oncol. 2024; 14:1383805.

PMID: 39450262 PMC: 11499224. DOI: 10.3389/fonc.2024.1383805.